Memorandum of Understanding aligns research, pharmaceutical execution, and global access initiatives Discovery to delivery—powered by science, strengthened by global access. WASHINGTON, D.C., April 30, 2026 — Melhem Scientific and Melhem Pharmaceuticals today announced the formal signing of a Memorandum of Understanding (MOU), establishing a unified strategic framework to accelerate collaboration across research, pharmaceutical access, and healthcare innovation. The agreement executed Feb....

Melhem Scientific proudly announces the appointment of Dr. Mohamad Zakaria Koubeissi as Vice Chair of the Board of Scientific Advisors, marking a significant advancement in the organization’s commitment to global scientific leadership and medical innovation. Dr. Koubeissi is an internationally respected physician-scientist, academic leader, and expert in neurology, epilepsy, and disorders of consciousness. He currently serves as the Meta A. Neumann Professor and Chair of the Department of...

Operation Elevate marked a defining step forward for Melhem Holdings and its subsidiaries. The discussions reinforced a clear reality: we are no longer operating within limited boundaries. We are building a globally positioned institution with the scale, discipline, and ambition to expand across the Middle East and Africa while strengthening our strategic ties with Europe. The meeting brought strong alignment across leadership. We conducted a focused review of Q1 performance, evaluated...